GE Healthcare and Theragnostics announce global commercial partnership for late stage PSMA diagnostic for prostate cancer

• Theragnostics’ novel PET tracer, GalliProst, will help visualize prostate cancer to enable personalized treatment.
• The two companies will leverage their combined scientific, commercial and market access expertise to work towards a commercial launch.

Chalfont St Giles, UK – October 9th 2019 – GE Healthcare and Theragnostics have entered into a global commercial partnership for a new Prostate-Specific Membrane Antigen (PSMA) PET/CT imaging agent. Theragnostics will lead the development of the tracer, GalliProst, while GE Healthcare will lead all pre-approval commercial preparations and as and when approval is received, all subsequent commercial and distribution activities.

Read more…

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...